P1048: MYF3001: A RANDOMIZED OPEN LABEL, PHASE 3 STUDY TO EVALUATE IMETELSTAT VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK MYELOFIBROSIS REFRACTORY TO JANUS KINASE INHIBITOR

Detalles Bibliográficos
Autores principales: Mascarenhas, J., Harrison, C. N., Kiladjian, J.-J., Komrokji, R. S., Koschmieder, S., Vannucchi, A. M., Berry, T., Redding, D., Sherman, L., Dougherty, S., Peng, L., Sun, L., Huang, F., Wan, Y., Feller, F. M., Rizo, A., Verstovsek, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430309/
http://dx.doi.org/10.1097/01.HS9.0000847060.14020.7d

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430309/
http://dx.doi.org/10.1097/01.HS9.0000847060.14020.7d

Ejemplares similares